Teriparatide topical
Alternative Names: PTH (1-34); Topical PTH 1-34Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator IGI
- Developer Manhattan Pharmaceuticals
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Parathyroid hormone receptor type 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 31 May 2009 Teriparatide topical is no longer licensed to Manhattan Pharmaceuticals
- 28 Dec 2005 Phase-II clinical trials in Psoriasis in USA (Topical)
- 13 Dec 2005 IGI has extended its exclusive license from Novavax for the use of Novasome® lipid vesicle encapsulation technology, micellar nanoparticles, and the Ultrasponge® Technology until December 2015